8:00 am
Christine Janus
Christine Janus
Chief Executive Officer
International Alliance of Dermatology Patient Organizations

Camilla Krogh Lauritzen
Camilla Krogh Lauritzen
Chief Patient Officer, Rare Diseases
Leo Pharma

8:15 am

As Pfizer’s Chief Patient Officer, Dr. Freda Lewis-Hall’s vision of patient-centricity is to serve patients around the world by seeking their voice and input, as well as understanding and responding to their needs. Biopharmaceutical companies can leverage its their resources to put patients first by advocating on behalf of patients who are counting on the delivery of innovative medicines and vaccines. To fulfill this mission, Dr. Lewis-Hall takes a multi-pronged approach, which centers on the following principles:

  • Deepen insight into patient needs to ensure that the patient voice is thoroughly embedded in research and development
  • Target gender, age, and race inequities in our health system to help patients’ access medicines
  • Extend the reach of health information and education initiatives to improve public health literacy
  • Galvanize thousands of employees to become individual ‘Chief Patient Officers’ in their own right
Freda Lewis-Hall
Freda Lewis-Hall, MD, DFAPA
Executive Vice President and Chief Patient Officer
Pfizer

8:30 am
Penny Bemus
Penny Bemus, MBA, JD
Senior Vice President, Commercial Strategy
Eversana

8:45 am

Health care stakeholders are in the midst of radical change, with a shift to value-based care and an increase in stakeholder consolidations and acquisitions. In addition to increased vertical integration, other disruptors are moving into health care, such as Amazon with its vision to reshape the way prescription drugs are delivered. Yet, amidst all of this change, these constants remain: organizations must focus managing costs, improving quality of care, and enhancing the patient experience. For pharmaceutical companies to ensure patients are at the center of their organization’s strategy, they must understand and adapt to this changing marketplace, meet the needs of their customers in the move to value-based care, be a valued partner in ensuring care coordination and improved patient experiences.

  • Explore current merger and acquisition trends to adjust care delivery and payment strategies
  • Identify changing stakeholder needs and incentives when developing partnerships with payers, providers, PBMs, and advocacy groups
  • Examine how changes in health care delivery are creating new opportunities for collaboration to improve patient outcomes
Todd Hobbs
Todd Hobbs, MD
Chief Medical Officer
NovoNordisk

John Rother
John Rother
Chief Executive Officer
National Coalition on HealthCare

Kristen Silberstein
Kristen Silberstein
Vice President, Patient Engagement & Chief Experience Officer
Holy Name Medical Center

Moderator:

Bill Campbell
Bill Campbell
Executive Vice President, Chief Commercial Officer
CSL Behring

9:30 am

In July 2018, CMS released a memo to Medicare Part D plans explaining CMS’s expectations regarding formulary exception requests. The memo also provided tools to plans to ensure that beneficiaries utilize low-cost generics when available on formulary and designed drug dashboards to ensure drug pricing transparency. As CMS continues to move health care toward greater implementation of value-based care and patient affordability, stakeholders must align organizational strategies to focus on quality. Explore recent changes to Medicare Part D, population health initiatives, and future CMS priorities for value-based care.

  • Gain a high-level overview of the recently release Medicare Part D changes
  • Learn about CMS efforts to improve population health and quality of care
  • Discuss the implications of future CMS priorities on all stakeholders
Barbara Connors
Barbara Connors
Chief Medical Officer
Office of the Regional Administrator, Centers for Medicare and Medicaid Services

10:45 am

Patients and caregivers can deliver insights that are crucial to the advancement of new therapies, market access, patient advocacy, and adherence. It is critical to map the patient journey to overcome roadblocks faced along the continuum of care. Ensuring patient-centricity isn’t just a buzzword requires manufacturers and key stakeholders to put themselves in the shoes of their patients. Hear directly from patients about their experiences with commercial and rare disease therapies, how they navigate the health care system, and where opportunities exist to elevate the patient voice within your organization’s strategies.

  • Gain insight into the real-life struggles of patients and caregivers
  • Explore best practices when implementing patient support services
  • Understand how to build interventions that improve adherence, foster advocacy collaborations, and advance market access

Patient Leaders:

Michael Mittelman
Michael Mittelman
Executive Director, Board Chairman, American Living Organ Donor Fund;
Patient Advisor, PCORI Ambassador;

Tiah Tomlin
Tiah Tomlin
Patient Advocate and Co-Founder
My Style Matters

Erin Wade
Erin Wade
Rare Disease Care Giver and Health Care Writer

Moderator:

Tara Herington
Tara Herington
Vice President, Cardinal Health Sonexus™ Access and Patient Support
Cardinal Health

11:30 am

The market access, pricing, and reimbursement landscape is rapidly evolving as stakeholders shift to a value-based health care system. The high price of some pharmaceuticals has made it difficult for patients to afford and access their medications, increasing the likelihood of non-adherence, discontinuation of therapy, and soaring out-of-pocket costs. Health plans and PBMs are using utilization management practices such as prior authorizations or step therapy to manage the cost of drugs to the system. At the same time, co-pay assistance and other patient support programs are used to help make prescriptions more affordable to patients. In order to improve the patient experience, stakeholders must collaborate and develop strategies to ensure patient access and overcome affordability challenges.

  • Understand how to design effective patient access and assistance programs
  • Discuss the implications of copay and coupon use on patient access
  • Gain insight into patient decision making to identify where opportunities to provide additional support may exist
  • Discuss ways stakeholders can improve collaboration to ensure access to necessary medicines
Sean Rapson
Sean Rapson
Vice President
Promidian, an EVERSANA company

Moderator:

Kathi Henson
Kathi Henson
Chief Patient Service Officer
Eversana

Advocacy:

Alan Balch
Alan Balch, PhD
Chief Executive Officer
Patient Advocate Foundation

Legal:

Gregg Shapiro
Gregg Shapiro
Assitant United States Attorney
District of Massachusetts

12:15 pm
1:45 pm

For rare disease products, it is particularly important to map the patient journey and integrate the patient perspective into key clinical business decisions to ensure an effective growth strategy. To succeed in a rare disease therapeutic area, manufacturers must tailor their organizational structure around rare diseases beyond the structure of a typical specialty company. Typical organizational structures have not traditionally been suited to rare disease therapies and can limit effectiveness and ability to realize maximum value from rare disease assets. Understand how to align research, development, market access, and marketing teams throughout the drug development process to foster success in orphan drug commercialization and ensure the patient is at the center of internal strategies.

  • Understand how to develop a patient-centric organizational structure
  • Define unmet patient needs and incorporate these insights into an internal growth strategy
  • Align internal teams to ensure successful commercialization of rare disease products

Moderator:

Rogerio Vivaldi
Rogerio Vivaldi, MD, MBA
President, Chief Executive Officer
Sigilon Therapeutics

Panelists:

Charmaine Gittleson
Charmaine Gittleson
Chief Medical Officer,
CSL Behring

David Snow
David Snow
Chief Business Officer
Eloxx Pharmaceuticals

Thorsten Thormann
Thorsten Thormann
Vice President of Research
LEO Pharma

2:30 pm

In order to be successful in today’s marketplace, manufacturers must identify a cross-functional team approach to orphan drug commercialization to meet the evolving needs of internal and external stakeholders. Understand how to align commercial and medical teams to advance products from pre-clinical stages through commercialization, achieve pharmaceutical product approvals, execute a global market strategy, and ensure launch readiness.

  • Understand the unique challenges associated with rare disease product development and commercialization
  • Leverage early commercial development to ensure launch readiness
  • Ensure stakeholder collaboration throughout product development to support market success
Haya Taitel
Haya Taitel
Executive Vice President, Chief Commercial Officer
Kadmon

3:45 pm

In today’s value-based health system, the scrutiny of high drug prices for rare disease therapies has caused drastic shifts in rare disease market access and commercialization. Payers have begun to implement restrictions to patient access, the Trump administration released the “American Patients First” blue print aimed to lower drug pricing, and ICER has become an increasingly bigger player in assessing comparative value. In order to improve market access to orphan drugs, manufacturers must navigate current reimbursement trends to develop a winning market access and commercialization strategy.

  • Examine the impact of reimbursement policies and legislation reform on commercialization
  • Review recent value and access assessments for rare disease and oncology products
  • Develop a commercialization strategy to ensure market access to rare disease therapies
Bhakti Arondekar
Bhakti Arondekar
Vice President, Global & US Immuno Oncology, Team Leader
Pfizer

4:30 pm

Rare diseases affect a small patient population with a high unmet need. In the past five years, the industry has seen an increase in the amount of rare disease therapies approved by the FDA. In order to meet the needs of patients and remain competitive, pharmaceutical manufacturers must develop a product launch strategy to ensure the success of new therapies on the market. Effectively collaborating with patients and payers during early lifecycle phases can support access planning. Hear successes of a recent rare disease product launch strategy to ensure market success.

  • Develop a product launch strategy tailored to rare disease therapies
  • Ensure stakeholder collaboration throughout product development to support market success
  • Discover effective product launch strategies to improve patient access
Diann Johnson
Diann Johnson
Executive Director, Business Development
Eversana

Bill O'Bryon
Bill O'Bryon
Managing Director of Digital, The Patient Experience Project
an Eversana Company